Literature DB >> 9717120

Superovulation with a high gonadotropin dose for in vitro fertilization: is it effective?

H Lashen1, W Ledger, A López Bernal, B Evans, D Barlow.   

Abstract

PURPOSE: Our purpose was to investigate the effect on the ovarian response of increasing the gonadotropin dose.
METHODS: We analyzed retrospectively the in vitro fertilization data for patients who had two cycles of treatment, with a higher dose in cycle 2. The patients were stratified according to age, ovarian response, and gonadotropin dose in the first cycle. The main outcome measure was the number of follicles, eggs, and embryos and the peak estradiol (E2) level.
RESULTS: The study included 244 patients. Patients in both age groups (n = 118, < or = 33 years; n = 126, > 33 years), low (n = 66) and intermediate (n = 145) responders, and patients who received < 225 IU follicle-stimulating hormone (n = 175) in cycle 1 had a better response in cycle 2. However, the high responders (n = 33) and those who received 225 or 300 IU follicle-stimulating hormone (n = 69) in cycle 1 showed a similar response in both cycles, except for a significantly higher E2 level in cycle 2.
CONCLUSIONS: Our results indicate that exceeding a daily dose of 300 IU is unrewarding.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9717120      PMCID: PMC3454804          DOI: 10.1007/bf02744938

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  6 in total

1.  Increasing the human menopausal gonadotropin dose--does the response really improve?

Authors:  C Pantos; S J Thornton; A L Speirs; I Johnston
Journal:  Fertil Steril       Date:  1990-03       Impact factor: 7.329

2.  A model for follicular selection and ovulation: lessons from superovulation.

Authors:  D T Baird
Journal:  J Steroid Biochem       Date:  1987       Impact factor: 4.292

Review 3.  Regulation of follicular oestrogen biosynthesis: a survey of current concepts.

Authors:  S G Hillier
Journal:  J Endocrinol       Date:  1981       Impact factor: 4.286

4.  The program for in vitro fertilization at Norfolk.

Authors:  H W Jones; G S Jones; M C Andrews; A Acosta; C Bundren; J Garcia; B Sandow; L Veeck; C Wilkes; J Witmyer; J E Wortham; G Wright
Journal:  Fertil Steril       Date:  1982-07       Impact factor: 7.329

5.  A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles.

Authors:  G M Lockwood; S M Pinkerton; D H Barlow
Journal:  Hum Reprod       Date:  1995-02       Impact factor: 6.918

6.  High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome.

Authors:  J A Land; M I Yarmolinskaya; J C Dumoulin; J L Evers
Journal:  Fertil Steril       Date:  1996-05       Impact factor: 7.329

  6 in total
  4 in total

Review 1.  Is there a recommended maximum starting dose of FSH in IVF?

Authors:  Luk Rombauts
Journal:  J Assist Reprod Genet       Date:  2007-06-17       Impact factor: 3.412

2.  Zygote versus embryo transfer: a prospective randomized multicenter trial.

Authors:  Brian Dale; Agnese Fiorentino; Maria Laura de Simone; Loredana di Matteo; Antonio Scotto di Frega; Martin Wilding; Peter Fehr; Emma Bassan; Cristoforo Lo Giudice; Antonio Maselli; Fulvio Cappiello; Fulvio Zullo
Journal:  J Assist Reprod Genet       Date:  2002-10       Impact factor: 3.412

3.  Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve.

Authors:  Dharmawijaya N Lekamge; Michelle Lane; Robert B Gilchrist; Kelton P Tremellen
Journal:  J Assist Reprod Genet       Date:  2008-10-30       Impact factor: 3.412

4.  Comparative prospective study of 2 ovarian stimulation protocols in poor responders: effect on implantation rate and ongoing pregnancy.

Authors:  Philippe Merviel; Rosalie Cabry-Goubet; Emmanuelle Lourdel; Aviva Devaux; Naima Belhadri-Mansouri; Henri Copin; Moncef Benkhalifa
Journal:  Reprod Health       Date:  2015-05-30       Impact factor: 3.223

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.